WO2000074661A3 - Amelioration de la solubilite de medicaments dans des systemes d'administration transdermique de medicaments et procedes d'utilisation - Google Patents

Amelioration de la solubilite de medicaments dans des systemes d'administration transdermique de medicaments et procedes d'utilisation Download PDF

Info

Publication number
WO2000074661A3
WO2000074661A3 PCT/US2000/015538 US0015538W WO0074661A3 WO 2000074661 A3 WO2000074661 A3 WO 2000074661A3 US 0015538 W US0015538 W US 0015538W WO 0074661 A3 WO0074661 A3 WO 0074661A3
Authority
WO
WIPO (PCT)
Prior art keywords
drugs
methods
drug delivery
delivery systems
transdermal drug
Prior art date
Application number
PCT/US2000/015538
Other languages
English (en)
Other versions
WO2000074661A2 (fr
Inventor
Sylvia Rossi-Montero
Juan Mantelle
David Kanios
David Houze
Original Assignee
Noven Pharma
Rossi Montero Sylvia
Juan Mantelle
David Kanios
David Houze
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noven Pharma, Rossi Montero Sylvia, Juan Mantelle, David Kanios, David Houze filed Critical Noven Pharma
Priority to AU53250/00A priority Critical patent/AU5325000A/en
Publication of WO2000074661A2 publication Critical patent/WO2000074661A2/fr
Publication of WO2000074661A3 publication Critical patent/WO2000074661A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition et un procédé d'administration transdermique régulée et continue d'un agent actif renfermant un porteur d'agent actif valide sur le plan pharmaceutique et un dérivé de cellulose qui produit un effet solubilisant et stabilisant sur les agents actifs incorporés.
PCT/US2000/015538 1999-06-05 2000-06-05 Amelioration de la solubilite de medicaments dans des systemes d'administration transdermique de medicaments et procedes d'utilisation WO2000074661A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU53250/00A AU5325000A (en) 1999-06-05 2000-06-05 Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13782799P 1999-06-05 1999-06-05
US06/137,827 1999-06-05

Publications (2)

Publication Number Publication Date
WO2000074661A2 WO2000074661A2 (fr) 2000-12-14
WO2000074661A3 true WO2000074661A3 (fr) 2001-06-28

Family

ID=22479199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/015538 WO2000074661A2 (fr) 1999-06-05 2000-06-05 Amelioration de la solubilite de medicaments dans des systemes d'administration transdermique de medicaments et procedes d'utilisation

Country Status (3)

Country Link
US (1) US6465004B1 (fr)
AU (1) AU5325000A (fr)
WO (1) WO2000074661A2 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
WO2000074661A2 (fr) 1999-06-05 2000-12-14 Noven Pharmaceuticals, Inc. Amelioration de la solubilite de medicaments dans des systemes d'administration transdermique de medicaments et procedes d'utilisation
US20020004065A1 (en) 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
DE10012908B4 (de) * 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
ES2239196T3 (es) * 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
GB0302662D0 (en) * 2003-02-05 2003-03-12 Strakan Ltd Transdermal granisetron
US7682626B2 (en) * 2003-02-07 2010-03-23 Roche Madison Inc. Polyvinylethers for delivery of polynucleotides to mammalian cells
US20050119340A1 (en) * 2003-06-13 2005-06-02 David Anderson Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents
DE10333393A1 (de) * 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US20050275372A1 (en) * 2004-06-14 2005-12-15 Crowell Jonathan C Power controller for managing arrays of smart battery packs
EP2216018B1 (fr) 2004-10-21 2012-04-04 Durect Corporation Systèmes d'administration transdermique
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
DE102004059674B4 (de) * 2004-12-10 2010-05-06 Acino Ag Transdermales System zur Abgabe von Scopolamin
JP4704764B2 (ja) * 2005-02-03 2011-06-22 日東電工株式会社 爪貼付用粘着組成物および爪用貼付剤
WO2007067624A2 (fr) 2005-12-06 2007-06-14 Tyco Healthcare Group Lp Composes bioabsorbables et compositions les contenant
AU2006321912B2 (en) * 2005-12-06 2012-07-12 Covidien Lp Carbodiimide crosslinking of functionalized polethylene glycols
EP1962867B1 (fr) * 2005-12-06 2013-06-19 Covidien LP Compositions chirurgicales biocompatibles
US7858078B2 (en) 2005-12-06 2010-12-28 Tyco Healthcare Group Lp Bioabsorbable surgical composition
AU2006321913B2 (en) * 2005-12-06 2012-08-02 Covidien Lp Biocompatible tissue sealants and adhesives
AU2006321856B2 (en) * 2005-12-08 2013-01-31 Covidien Lp Biocompatible surgical compositions
US8449714B2 (en) 2005-12-08 2013-05-28 Covidien Lp Biocompatible surgical compositions
EP1998756A2 (fr) * 2006-02-27 2008-12-10 Noven Pharmaceuticals, Inc. Compositions et procédés d'apport de médicaments amino-fonctionnels
WO2007145996A2 (fr) * 2006-06-06 2007-12-21 Dow Corning Corporation Formule hybride silicone-acrylate et sa méthode de fabrication
US8569416B2 (en) 2006-06-06 2013-10-29 Dow Corning Corporation Single phase silicone acrylate formulation
US8614278B2 (en) 2006-06-06 2013-12-24 Dow Corning Corporation Silicone acrylate hybrid composition and method of making same
EP1987815A1 (fr) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Compositions pharmaceutiques à base d'agonistes dopaminergiques administrables par voie oro-naso-pharyngale pour la prévention et/ou le traitement de membres sans repos
EP2259780A2 (fr) * 2008-02-28 2010-12-15 Syntropharma Limited Composition pharmaceutique comprenant de la naltrexone
WO2009119673A1 (fr) 2008-03-25 2009-10-01 帝國製薬株式会社 Préparation absorbable par voie transdermique
US8734944B2 (en) * 2008-07-28 2014-05-27 Dow Corning Corporation Composite article
KR101452788B1 (ko) 2009-04-24 2014-10-21 헨켈 유에스 아이피 엘엘씨 실리콘 아크릴 혼성 중합체-기재 접착제
WO2011035310A2 (fr) * 2009-09-21 2011-03-24 Virginia Tech Intellectual Properties, Inc. Esters de matières cellulosiques et de diacides et leur procédé de fabrication
JP5665116B2 (ja) * 2009-11-20 2015-02-04 日東電工株式会社 貼付剤および貼付製剤
EP2584016A1 (fr) 2011-10-21 2013-04-24 Dow Corning Corporation Formulation d'acrylate de silicone à phase unique
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
JP2013139554A (ja) 2011-11-29 2013-07-18 Dow Corning Corp シリコーンアクリレートハイブリッド組成物及び該組成物の製造方法
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
WO2014078576A2 (fr) 2012-11-14 2014-05-22 Abon Pharmaceuticals, Llc Système d'administration d'un médicament par voie orale transmuqueuse
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
EP3775086B1 (fr) 2018-04-05 2022-09-14 3M Innovative Properties Company Adhésif en gel comprenant un mélange réticulé de polydiorganosiloxane et de polymère acrylique
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156080A1 (fr) * 1984-03-05 1985-10-02 Nitto Denko Corporation Préparation pharmaceutique adhésive du type à absorption percutanée
EP0262422A1 (fr) * 1986-09-01 1988-04-06 Teikoku Seiyaku Kabushiki Kaisha Forme de dosage à libération prolongée
WO1992015289A1 (fr) * 1991-02-27 1992-09-17 Noven Pharmaceuticals, Inc. Compositions et procedes d'administration locale d'agents pharmaceutiquement actifs
WO1996000072A1 (fr) * 1994-06-23 1996-01-04 The Procter & Gamble Company Traitement du besoin de nicotine et/ou des symptomes de manque du fumeur au moyen d'une composition contenant de la nicotine et de la cafeine ou de la xanthine, pouvant etre administree par voie transdermique ou a travers les muqueuses
EP0913158A1 (fr) * 1997-09-17 1999-05-06 Permatec Technologie Ag Patch transdermal comprenant une combinaison de deux ou plus de deux acides ou alcools gras comme agents favorisant la pénétration cutanée

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE95430T1 (de) 1984-12-22 1993-10-15 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster.
US4883669A (en) * 1985-02-25 1989-11-28 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration
JPH0744940B2 (ja) * 1986-12-24 1995-05-17 ライオン株式会社 口腔貼付用基材
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
US5417671A (en) 1990-05-23 1995-05-23 Jackson; Richard R. Medical devices having local anesthetic effect and methods of their manufacture
US5232702A (en) 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
DE4230588C1 (de) * 1992-09-12 1993-10-07 Lohmann Therapie Syst Lts Dexpanthenol-haltiges Pflaster zur transdermalen Applikation von Steroidhormonen und Verfahren zu seiner Herstellung
US5883115A (en) 1992-11-09 1999-03-16 Pharmetrix Division Technical Chemicals & Products, Inc. Transdermal delivery of the eutomer of a chiral drug
US5523095A (en) 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
DE19500662C2 (de) 1995-01-12 2001-04-26 Lohmann Therapie Syst Lts Estradiolhaltiges Pflaster und seine Verwendung
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
HUP9601442A3 (en) 1995-07-25 1999-03-29 Panacea Biotec Ltd Nes antinflammatory and analgetic pharmaceutical compositions, containing nimesulid for transdermal use, and process for producing them
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5906814A (en) 1995-12-07 1999-05-25 The Andrew Jergens Company Topical film-forming compositions
WO1998039042A1 (fr) 1997-03-07 1998-09-11 Jackson Richard R Matiere plastique pour materiel d'anesthesie ou d'administration de medicaments, produits, systemes et procedes medicaux associes
GB9720470D0 (en) 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
WO2000074661A2 (fr) 1999-06-05 2000-12-14 Noven Pharmaceuticals, Inc. Amelioration de la solubilite de medicaments dans des systemes d'administration transdermique de medicaments et procedes d'utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0156080A1 (fr) * 1984-03-05 1985-10-02 Nitto Denko Corporation Préparation pharmaceutique adhésive du type à absorption percutanée
EP0262422A1 (fr) * 1986-09-01 1988-04-06 Teikoku Seiyaku Kabushiki Kaisha Forme de dosage à libération prolongée
WO1992015289A1 (fr) * 1991-02-27 1992-09-17 Noven Pharmaceuticals, Inc. Compositions et procedes d'administration locale d'agents pharmaceutiquement actifs
WO1996000072A1 (fr) * 1994-06-23 1996-01-04 The Procter & Gamble Company Traitement du besoin de nicotine et/ou des symptomes de manque du fumeur au moyen d'une composition contenant de la nicotine et de la cafeine ou de la xanthine, pouvant etre administree par voie transdermique ou a travers les muqueuses
EP0913158A1 (fr) * 1997-09-17 1999-05-06 Permatec Technologie Ag Patch transdermal comprenant une combinaison de deux ou plus de deux acides ou alcools gras comme agents favorisant la pénétration cutanée

Also Published As

Publication number Publication date
WO2000074661A2 (fr) 2000-12-14
AU5325000A (en) 2000-12-28
US6465004B1 (en) 2002-10-15

Similar Documents

Publication Publication Date Title
WO2000074661A3 (fr) Amelioration de la solubilite de medicaments dans des systemes d'administration transdermique de medicaments et procedes d'utilisation
WO2002045701A3 (fr) Inhibition de la cristallisation de medicament dans des systemes d'administration transdermique et procedes d'utilisation
AU2003240949A1 (en) Active agent delivery systems and methods for protecting and administering active agents
WO2000045792A8 (fr) Preparations de particules hydrogel
WO2001043749A3 (fr) Implant pharmacologique contenant des composants a liberation immediate et a liberation prolongee et procede d'administration
AU5343899A (en) Catheter drug delivery system and method for use
AU8659901A (en) Active agent delivery systems and methods for protecting and administering active agents
MXPA04006731A (es) Sistema de administracion de farmacos que comprenden rapamicina y derivados de la misma para la prevencion y tratamiento de enfermedades vasculares.
AU1534899A (en) Device and method for non-occlusive localized drug delivery
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
WO2001087342A3 (fr) Systemes d'administration de medicaments/medicaments destines a la prevention et au traitement de maladies vasculaires
AU2879100A (en) Formulation and system for intra-oral delivery of pharmaceutical agents
MY129435A (en) Pharmaceutical microemulsion preconcentrates
AU2938100A (en) Transdermal drug delivery system and method
EP1490090A4 (fr) Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
AU2002231058A1 (en) Biologically active agent delivery apparatus and method
EP2305251A3 (fr) Composition pharmaceutique comprenant de l'acide clavulanique ou un de ses dérivés pour traiter les désordres sexuels
WO2004039426A3 (fr) Systeme d'administration transdermique de medicaments insolubles dans l'eau
AU3206299A (en) Method and apparatus for combining injury-mediated therapy and drug delivery
EE05506B1 (et) Ravimi manustamise vahend eriti progestiinide ja”strogeenide manustamiseks
GEP20032941B (en) Gastroprotected Omerprazole Microgranules, Method for Obtaining Same and Pharmaceutical Preparations
AU9547598A (en) Analgesic compositions
AU5673399A (en) Compositions and methods for treating intracellular infections
EP1275373A4 (fr) Systeme d'administration de medicament empechant l'interaction pharmacocinetique entre les medicaments et procede correspondant
EP1325753A3 (fr) Elements biocompatibles pour la liberation controlée de principes actifs aux tissus et méthodes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP